Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
11.69
-0.11 (-0.93%)
At close: Jan 2, 2026, 4:00 PM EST
13.80
+2.11 (18.05%)
Pre-market: Jan 5, 2026, 8:53 AM EST
Passage Bio Market Cap
Passage Bio has a market cap or net worth of $37.16 million as of January 5, 2026. Its market cap has decreased by -16.68% in one year.
Market Cap
37.16M
Enterprise Value
8.72M
1-Year Change
-16.68%
Ranking
Category
Stock Price
$11.69
Market Cap Chart
Since February 28, 2020, Passage Bio's market cap has decreased from $956.75M to $37.16M, a decrease of -96.12%. That is a compound annual growth rate of -42.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 2, 2026 | 37.16M | -0.93% |
| Dec 31, 2025 | 37.51M | 7.08% |
| Dec 31, 2024 | 35.03M | -36.74% |
| Dec 29, 2023 | 55.37M | -26.45% |
| Dec 30, 2022 | 75.28M | -78.09% |
| Dec 31, 2021 | 343.58M | -70.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Feb 28, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 967.33B |
| Johnson & Johnson | 499.57B |
| AbbVie | 405.28B |
| UnitedHealth Group | 304.72B |
| AstraZeneca | 284.35B |
| Novartis AG | 266.00B |
| Merck & Co. | 264.21B |
| Novo Nordisk | 230.76B |